Alnylam Pharmaceuticals ($ALNY) Drops -17% in 30 Days: What's Behind the Slide (See the latest news for any ticker on Tickeron.) ALNY shares declined roughly 17% over the last 30 days, falling from about $266 in early September to near $220 by early October. The drop extends a broader slide of about 30% over the last quarter and more than 44% year-to-date. Investor caution has centered on Amvuttra growth momentum, a cut to full-year revenue guidance, and reduced analyst price targets. Longer-term debates over the expanding RNAi pipeline and competitive dynamics in ATTR cardiomyopathy remain central to the stock's outlook. $PHAT $UTHR $AXON $MDGL